このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

INHANCE ステムレス リバースショルダー IDE

2026年11月2日 更新者:DePuy Orthopaedics

INHANCE ステムレストータルリバースショルダーシステムのランダム化前向き多施設研究

2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

There is one primary effectiveness endpoint and there are three primary safety endpoints:

  1. Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative

  2. Primary safety endpoint(s):

    1. No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
    2. No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
    3. No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years

The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.

研究の種類

介入

入学 (実際)

168

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Florida
      • Atlantis、Florida、アメリカ、33462
        • Orthopedic Center of Palm Beach County
    • Massachusetts
      • Waltham、Massachusetts、アメリカ、02451
        • Boston Bone & Joint Institute BBJI Formerly BSSC
    • Michigan
      • Grand Rapids、Michigan、アメリカ、49503
        • Trinity Health Grand Rapids
    • Missouri
      • Columbia、Missouri、アメリカ、65201
        • Missouri Orthopaedic Institute (MOI)
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28207
        • OrthoCarolina Research Institute Charlotte
      • Raleigh、North Carolina、アメリカ、27609
        • Duke Orthopaedics of Raleigh
    • Ohio
      • Akron、Ohio、アメリカ、44333
        • Crystal Clinic Orthopaedic Center
      • Cincinnati、Ohio、アメリカ、45219
        • Lindner Research Center
      • Cleveland、Ohio、アメリカ、44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Eugene、Oregon、アメリカ、97401
        • Slocum Center for Orthopaedics and Sports Medicine
    • Pennsylvania
      • Bethlehem、Pennsylvania、アメリカ、18015
        • St. Luke's University Health Network
      • Philadelphia、Pennsylvania、アメリカ、19107
        • Rothman Orthopaedics Institute
    • Tennessee
      • Columbia、Tennessee、アメリカ、38401
        • MTBJ a division of Tennessee Orthaepedic Alliance
    • Utah
      • Salt Lake City、Utah、アメリカ、84108
        • University of Utah
    • Virginia
      • Fredericksburg、Virginia、アメリカ、22408
        • Mary Washington Orthopedics in affiliation with FOA

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

22年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
  2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
  3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
  4. Individuals who are willing and able to return for follow-up as specified by the study protocol.
  5. Individuals who are a minimum age of 22 years at the time of consent.
  6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.

Exclusion Criteria:

  1. BMI > 40 kg/m2
  2. Individuals have active, uncontrolled local infection or systemic infection.
  3. Patients who have not reached skeletal maturity, regardless of age.
  4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
  5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
  6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
  7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
  8. Revision of a failed hemi, total or reverse shoulder arthroplasty.
  9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
  10. Individuals who are bedridden per the Investigator's determination.
  11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
  12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
  14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
  15. Patient has a medical condition with less than 2 years life expectancy.
  16. Patients who are known to be pregnant or breastfeeding.
  17. Known polyethylene and/or metal sensitivity or allergy.
  18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
  19. Otherwise determined by the investigator to be medically unsuitable for participation in this study
  20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:INHANCE Stemless Reverse

INHANCE(TM) Stemless Reverse Total Shoulder

Uncemented Reverse Total Shoulder

アクティブコンパレータ:INHANCE Stemmed Reverse

INHANCE(TM) Stemmed Reverse Total Shoulder

Uncemented Reverse Total Shoulder

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Constant Murley Score (CMS)
時間枠:Pre-op, 2 years

Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 2 years
Removal of any system component
時間枠:2 year

No removal of any system component

2 year
Revision of any system component
時間枠:2 year

No revision of any system component

2 year
Reoperation of any system component
時間枠:2 year

No reoperation of any system component

2 year
Supplemental Fixation of any system component
時間枠:2 year

No supplemental fixation of any system component

2 year
Radiolucent Lines (Humeral & Glenoid)
時間枠:2 year

No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones

2 year
Migration and Tilt (Humeral & Glenoid)
時間枠:2 year

No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component

2 year

二次結果の測定

結果測定
メジャーの説明
時間枠
Constant Murley Score (CMS)
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year, 2 year
EQ-5D-5L and EQ-VAS
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Survivorship
時間枠:2 year

Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method.

2 year
Complications
時間枠:2 year

The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs

2 year

その他の成果指標

結果測定
メジャーの説明
時間枠
Constant Murley Score (CMS)
時間枠:Pre-op, 3-month, 6-month, 1 year

Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year
EQ-5D-5L and EQ-VAS
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Range of Motion
時間枠:Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative

Pre-op, 3-month, 6-month, 1 year, 2 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月4日

一次修了 (推定)

2027年11月10日

研究の完了 (推定)

2028年10月30日

試験登録日

最初に提出

2024年2月27日

QC基準を満たした最初の提出物

2024年3月15日

最初の投稿 (実際)

2024年3月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • DSM202108
  • DSM202108 (その他の識別子:DePuy Orthopaedics)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。